Lenacapavir

5 trials 2 recruiting JAnti-infectives

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

2 Sponsors

4 Countries

Phase III

Phase II/III

Phase III: 2 Phase II/III: 3

Sponsors using this IMP

Gilead Sciences Inc. 4 Inst Medecine Epidemiologie Appliquee 1

All trials

5 total

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Recruiting

2023-510022-33-00 Phase III 4 countries Gilead Sciences Inc.
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 Recruiting

2023-509428-16-00 Phase II/III 2 countries Gilead Sciences Inc.
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) Ended

2023-507891-31-00 Phase II/III 1 country Gilead Sciences Inc.
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Ended

2022-500929-33-01 Phase II/III 4 countries Gilead Sciences Inc.
Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA Ended

2024-516028-33-01 Phase III 1 country Inst Medecine Epidemiologie Appliquee

Showing 1–5 of 5 trials

← All drugs A–Z